Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.67 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.67 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.67 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.67 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.67 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.67 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.67 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.67 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.67 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | VDR | P11473 | 6/20 | 0.66 |
| ▸ | CASP7 | P55210 | 3/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10906860 | 0.88 | GPBAR1 (0.74) | GPBAR1HSD17B10TDP1AKR1B10AKR1B1 | |
| SCHEMBL381612 | 0.88 | GPBAR1 (0.74) | GPBAR1HSD17B10TDP1AKR1B10AKR1B1 | |
| SCHEMBL4751618 | 0.88 | GPBAR1 (0.74) | GPBAR1HSD17B10TDP1AKR1B10AKR1B1 | |
| SCHEMBL7124131 | 0.87 | GPBAR1 (0.49) | GPBAR1HSD17B10TDP1AKR1B10AKR1B1 | |
| SCHEMBL1492255 | 0.87 | GPBAR1 (0.49) | GPBAR1HSD17B10TDP1AKR1B10AKR1B1 | |
| SCHEMBL4182461 | 0.87 | GPBAR1 (0.51) | GPBAR1HSD17B10TDP1AKR1B10AKR1B1 | |
| SCHEMBL977813 | 0.85 | VDR (0.69) | GPBAR1HSD17B10TDP1AKR1B10AKR1B1 | |
| SCHEMBL5154446 | 0.85 | VDR (0.69) | GPBAR1HSD17B10TDP1AKR1B10AKR1B1 | |
| SCHEMBL15156945 | 0.85 | VDR (0.69) | GPBAR1HSD17B10TDP1AKR1B10AKR1B1 | |
| SCHEMBL1492159 | 0.85 | CYP2D6 (0.62) | LMNAMEN1KMT2ATP53USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470553-B1 | POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS | QING BILE THERAPEUTICS INC (CA) | 2024-06-19 | — | — | EP | claimed |
| US-20220227804-A1 | COMBINATION OF A POLYHYDROXYLATED BILE ACID AND A FARNESOID X RECEPTOR AGONIST | QING BILE THERAPEUTICS INC. (CA) | 2022-07-21 | — | — | US | claimed |
| US-20200078374-A1 | POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS | QING BILE THERAPEUTICS INC. (CA) | 2020-03-12 | — | — | US | claimed |
| US-10543220-B2 | Polyhydroxylated bile acids for treatment of biliary disorders | QING BILE THERAPEUTICS INC. (CA) | 2020-01-28 | — | — | US | claimed |
| US-20160184325-A1 | POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS | QING BILE THERAPEUTICS INC. (CA) | 2016-06-30 | — | — | US | claimed |
| US-9295677-B2 | Polyhydroxylated bile acids for treatment of biliary disorders | QING BILE THERAPEUTICS INC. (CA) | 2016-03-29 | — | — | US | claimed |
| EP-2470553-A1 | POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS | British Columbia Cancer Agency Branch (CA) | 2012-07-04 | — | — | EP | claimed |
| WO-2011022838-A1 | POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2011-03-03 | — | — | WO | claimed |
| WO-2009105897-A1 | POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2009-09-03 | — | — | WO | claimed |
| EP-2470553-B1 | POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS | QING BILE THERAPEUTICS INC (CA) | 2024-06-19 | — | — | EP | disclosed |
| US-20220227804-A1 | COMBINATION OF A POLYHYDROXYLATED BILE ACID AND A FARNESOID X RECEPTOR AGONIST | QING BILE THERAPEUTICS INC. (CA) | 2022-07-21 | — | — | US | disclosed |
| US-20200078374-A1 | POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS | QING BILE THERAPEUTICS INC. (CA) | 2020-03-12 | — | — | US | disclosed |
| US-10543220-B2 | Polyhydroxylated bile acids for treatment of biliary disorders | QING BILE THERAPEUTICS INC. (CA) | 2020-01-28 | — | — | US | disclosed |
| EP-2758060-B1 | ROR GAMMA MODULATORS FOR TREATING DIABETES II COMPLICATIONS | ETH Zürich (CH) | 2017-11-29 | — | — | EP | disclosed |
| US-9295677-B2 | Polyhydroxylated bile acids for treatment of biliary disorders | QING BILE THERAPEUTICS INC. (CA) | 2016-03-29 | — | — | US | disclosed |
| US-20120277198-A1 | POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS | QING BILE THERAPEUTICS INC. (CA) | 2012-11-01 | — | — | US | disclosed |
| EP-2470553-A1 | POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS | British Columbia Cancer Agency Branch (CA) | 2012-07-04 | — | — | EP | disclosed |
| US-20110263546-A1 | Polyhydroxylated Bile Acids for Treatment of Biliary Disorders | BRITISH COLUMBIA CANCER AGENCY (CA) | 2011-10-27 | — | — | US | disclosed |
| WO-2011022838-A1 | POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2011-03-03 | — | — | WO | disclosed |
| WO-2009105897-A1 | POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200078374-A1 | POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS | NR1H4, SLC10A1, SLC10A2 | GPBAR1 4/4885HSD17B10 57/4885TDP1 4065/4885 |
| US-20120277198-A1 | POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS | NR1H4, SLC10A1, SLC10A2 | GPBAR1 4/4885HSD17B10 56/4885TDP1 4057/4885 |
| US-20220227804-A1 | COMBINATION OF A POLYHYDROXYLATED BILE ACID AND A FARNESOID X RECEPTOR AGONIST | NR1H4, GPBAR1, SLC10A1 | GPBAR1 2/4885HSD17B10 309/4885TDP1 4128/4885 |
| US-20160184325-A1 | POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS | NR1H4, SLC10A1, SLC10A2 | GPBAR1 4/4885HSD17B10 57/4885TDP1 4056/4885 |
| US-10543220-B2 | Polyhydroxylated bile acids for treatment of biliary disorders | NR1H4, SLC10A1, SLC10A2 | GPBAR1 4/4885HSD17B10 56/4885TDP1 4057/4885 |
| US-20110263546-A1 | Polyhydroxylated Bile Acids for Treatment of Biliary Disorders | NR1H4, SLC10A1, SLC10A2 | GPBAR1 4/4885HSD17B10 77/4885TDP1 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.